Caribou Biosciences said Monday that its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.

The study results, while preliminary, are comparable to benchmarks set by currently approved, patient-specific CAR-T therapies for lymphoma — an achievement that could push the off-the-shelf CAR-T field forward after years of setbacks and broaden access to cell therapy for blood cancers.

In the study, 64% of patients treated with Caribou’s therapy, called vespa-cel (formerly CB-010), achieved a complete response. The overall response rate was 82%. At one year, 51% of the vespa-cel-treated patients remain alive without their cancer worsening.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page